Capricor Therapeutics Inc CAPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
-
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
-
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
-
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
-
CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR
-
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
-
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline
Trading Information
- Previous Close Price
- $8.94
- Day Range
- $8.99–9.22
- 52-Week Range
- $2.96–40.37
- Bid/Ask
- $9.17 / $9.24
- Shares Outstanding
- 58.14M
- Market Cap
- $524.41M
- Volume/Avg
- 389,474 / 7M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 231
- Website
- https://www.capricor.com
Valuation
|
Metric
|
CAPR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.11 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CAPR
|
|---|---|
Quick Ratio | 7.22 |
Current Ratio | 7.35 |
Interest Coverage | — |
Quick Ratio
CAPR
Profitability
|
Metric
|
CAPR
|
|---|---|
Return on Assets (Normalized) | −41.80% |
Return on Equity (Normalized) | −53.74% |
Return on Invested Capital (Normalized) | −47.42% |
Return on Assets
CAPR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|g&y&Qq | LOCK|VJZYv | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|W%#&W>j | LOCK|Y$R#r | $76B | |||
| Moderna Inc
MRNA
| LOCK|Y@cFy%b | LOCK|%%H | $75B | |||
| argenx SE ADR
ARGX
| LOCK|>@PN<%L | LOCK|n!> | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|RQ$Rq? | LOCK|#% | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|sgR>^N@ | LOCK|!V^f | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|r!h>JVX | LOCK|YzzM | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|R&TRC#q | LOCK|tX | $24B | |||
| Incyte Corp
INCY
| LOCK|>$hc#d | LOCK|%w | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|HmkKVM | LOCK|VF | $15B |
United States